# Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

> **NCT01940848** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 243 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** STW5 (Iberogast, BAY98-7411)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01940848
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-11
- **Primary completion:** 2017-10-25
- **Final completion:** 2017-10-25
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940848, "Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01940848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*